Gene/Protein Disease Symptom Drug Enzyme Compound
Pivot Concepts:   Target Concepts:
Query: UMLS:C0016053 (fibromyalgia)
 4,687 document(s) hit in 31,850,051 MEDLINE articles (0.00 seconds)

A 10-day open trial with Tropisetron, the selective serotonin type 3 receptor antagonist, in a dose of 5 mg daily was undertaken in 19 patients with the primary fibromyalgia syndrome (FB). Before and after the therapy, pain was assessed using a visual analogue scale and a pain score. All the patients were asked about the presence and intensity of vegetative and functional symptoms. Moreover, the tenderness at the 24 typical tender points at baseline and at the end of the therapy was evaluated. A statistically significant improvement of all examined parameters was observed after the therapy. The efficacy of Tropisetron in a dose of 5 mg daily was comparable with the results obtained in a previously reported trial with a dose of 10 or 15 mg per day, but the frequency of gastric troubles decreased (21% vs. 60%). The hypothesis about the existence of two subgroups of patients with FB is also discussed.
Mater Med Pol
PMID:The 5-HT3 blockers in the treatment of the primary fibromyalgia syndrome: a 10-day open study with Tropisetron at a low dose. 908 21

Botulinum toxin (BTx) has been administered for many years in the treatment of dystonias with great success. Its effectiveness is comparable with the best drugs. It was observed during spasmodic torticollis treatment that pain disappears as first before clinical improvement of dystonia. Different mechanisms of influence of BTx on pain are discussed. BTx was tried in tension headache, cluster headache, migraine, fibromyositis, painful cramps with varying results. It is possible that BTx will be useful in many other types of pain.
Neurol Neurochir Pol 1998
PMID:[Botulinum toxin in the treatment of pain]. 960 54

Fibromyalgia (FM) is a chronic disorder characterised by musculoskeletal pain, diffuse pain in "tender points", fatigue, sleep disturbances, and multiorgan functional disorders. The case is presented of a 16-year-old girl suffering from fibromyalgia. The clinical course, problems with diagnosis and treatment have been analysed.
Pol Merkur Lekarski 2003 May
PMID:[Fibromyalgia syndrome: a case of a 16-year old girl: diagnosis, clinical and therapeutic problems]. 1293 24

Fibromyalgia is a fairly common syndrome characterized by chronic, widespread musculoskeletal pain, multiple "tender points", fatigue, sleep disturbance, stiffness and other symptoms such as headache, dizziness, trouble with concentration, irritable bowel syndrome, urinary urgency, depression. Fibromyalgia may occur at any age, even in childhood, is much more common in women than in men. The cause of fibromyalgia is unknown. It is difficult to diagnose because many of the symptoms are similar to symptoms of other disorders. There are no laboratory tests that can confirm a diagnosis of fibromyalgia. Average time from onset to diagnosis is 5-8 years. Treatment of fibromyalgia requires a comprehensive approach.
Pol Merkur Lekarski 2004 Jan
PMID:[Fibromyalgia syndrome--pathogenesis, diagnosis, and treatment problems]. 1507 33

Epidemiological studies confirm frequent appearance of pain symptoms in depressive patients and a marked prevalence of depression in pain conditions. These observations seem to point at a close intertwining between mood regulation and pain perception. In the pathogenesis of both depression and pain symptoms, an important role has been attributed to disturbances of serotonergic and noradrenergic neurotransmission as well as to neuropeptides such as opioids and substance P. In mood regulation as well as in the perception and emotional dimension of pain stimuli, such brain structures as the amygdala, anterior cingulate cortex and prefrontal cortex are of main significance. The action of antidepressant drugs results in a normalization of the activity of those neurotransmitter systems and brain structures. It was found that dual action antidepressants (i.e. influencing both serotonergic and noradrenergic system) such as tricyclic antidepressants and new generation drugs (venlafaxine, milnacipram, duloxetine, mirtazapine) exert a stronger antidepressant effect and possess a broader therapeutic spectrum, including also an effect on pain symptoms. These drugs have been also increasingly used for the treatment of pain symptoms in somatic illnesses (e.g. diabetic neuropathy, fibromyalgia).
Psychiatr Pol
PMID:[Depression and pain: novel clinical, neurobiological and psychopharmacological data]. 1635 93

The association between migraine and functional gastrointestinal disorders has been confirmed by many clinical observations and epidemiological studies. In most patients during the attacks of migraine, apart from various neurological and vascular symptoms, gastrointestinal disturbances occur including nausea, vomiting, abdominal pain or diarrhea. Functional gastrointestinal disorders, such as irritable bowel syndrome (IBS), are reported in migraine patients in periods between the attacks as well. On the other hand 23-53% of IBS patients have frequent headaches. Migraine and IBS often coexist with fibromyalgia and other chronic pain syndromes and functional disorders. Migraine and IBS affect approximately 10-20% of the general population, usually young adults. Both diseases are more prevalent in women, perhaps due to the role of estrogen in their pathogenesis. Looking for the common pathogenetic mechanisms of IBS and migraine the role of the brain-gut axis, neuroimmune and neuroendocrine interactions are being considered. The influence of stress on symptom occurrence and severity seems to be associated with hyperactivity of the hypothalamic-pituitary-adrenal axis. The enteric nervous system as a source of numerous neurotransmitters and visceral reflexes is a plausible common pathogenic link between IBS and migraine. In particular serotonin being the main neurotransmitter of the gastrointestinal tract plays a relevant role in the pathogenesis of IBS as well as migraine. Nowadays, agonists and antagonists of serotoninergic receptors are the most efficacious drugs for IBS and migraine therapy. Some side effects of triptans, 5-HT(1B/D) agonists, used in migraine treatment may be connected with the influence of triptans on the gastrointestinal functions. A better understanding of the relationship between migraine and IBS may result in more effective treatment of both diseases.
Neurol Neurochir Pol 2005
PMID:[Migraine and irritable bowel syndrome]. 1641 71

Musculoskeletal pains are one of the most common complaints reported by patients. In 1972, Smythe described the generalized pain and tenderness on palpation at specific points and, 4 years later, the term fibromyalgia was introduced for determining the disease syndrome. The etiology and pathogenesis of fibromyalgia are still unknown. This disease appears probably multi-factorial. It is considered that the changes in the neuronal activity in the central nervous system, abnormal metabolism of biogenic amines and immunological disorders may among other things, contribute to the development of the disease. The complaints are non characteristic and highly sujective, which makes it substantially difficult to differentiate between fibromialgia and both chronic fatigue syndrome and psychosomatic diseases. The treatment of fibromyalgia is complex and long-term. The antidepressants and psychotherapy is of vital importance. The effectiveness of locally used agents is also being emphasized. Fibromyalgia has become a serious social problem in the well developed countries in the recent years. Therefore, of importance are efforts to appropriately diagnose fibromyalgia and to implement its appropriate treatment that resolves disease symptoms in a possibly maximum degree.
Pol Arch Med Wewn 2009 Mar
PMID:Fibromyalgia: pathogenetic, diagnostic and therapeutic concerns. 1951 45

Two main types of myalgia that are not inflammatory are fibromyalgia (FB) and myofasical pain (MFP). In both of them during diagnosing tender points (characteristic for fibromyalgia) and trigger points (MTrP--characteristic for myofasical pain) are of key importance. A great degree of similarity together with the inability to differentiate between those points result in wrong diagnosis and, as a consequence, failure of therapy. Additional difficulties are caused by the lack of unity in nomenclature, as in literature the term tender point and trigger point are used interchangeably. Moreover, some centres question the existence of fibromyalgia and myofascial pain as separate pain entities.
Chir Narzadow Ruchu Ortop Pol
PMID:[Tender points and trigger points--differences and similarities]. 2020 36

Fibromyalgia is a disorder of the pain perception, which may, but need not be associated with depression. Modern science does not allow to put an equal sign between the two diseases. However, at least in some people, can be seen as a variant of depression, fibromyalgia. Studies indicate that 50-80 per cent, people with fibromyalgia can recognize depression. The article discusses the current state of knowledge on the role of physical activity, psychosomatic health treatments, physical therapy, relaxation techniques and education for patients with fibromyalgia. The best results, combine different therapies. The use of drugs is to reduce pain, improve mood and improve sleep quality. Various forms of drug-free treatment and help to restore the efficiency of dealing with complaints. In the treatment of fibromyalgia using different forms of therapy, tailored to the individual needs of the patient. The most common are: balneotherapy, exercise, cryotherapy, cognitive-behavioral psychotherapy and other forms of psychotherapy--in order to develop methods to combat stress and depressed mood, relaxation techniques, acupuncture, massage.
Pol Merkur Lekarski 2013 Jun
PMID:[Briquet syndrome in patients with fibromyalgia]. 2388 37

Burning mouth syndrome (BMS) is a chronic pain condition characterized by pain, burning sensations and dryness within an oral mucosa, without any clinical changes of the latter. It occurs approximately seven times more frequently in women, mostly in perimenopausal age. The psychiatric aspect of BMS is significant: the most frequent co-morbidities are depression and anxiety disorders, and a number of psychotropic drugs play an essential role in its treatment. In the present review, the most important pathogenic and treatment concepts of BMS have been discussed. The BMS may be similar to neuropathic pain and has some related pathogenic elements with fibromyalgia and the restless leg syndrome. In primary BMS, the features of presynaptic dysfunction of dopaminergic neurons and deficiency of endogenous dopamine levels have been demonstrated. Other neurotransmitters such as serotonin, noradrenaline, histamine as well as hormonal and inflammatory factors may also play a role in the pathogenesis of BMS. In the pharmacological treatment of BMS a variety of drugs have been used including benzodiazepines, anticonvulsants, antidepressants and atypical antipsychotic drugs. In the final part of the paper, the possibility of using atypical antipsychotic drug, olanzapine, in the treatment of BMS has been discussed. In the context of the recent studies on this topic, a case of female patient with the BMS lasting more than ten years has been mentioned, in whom the treatment with olanzapine brought about a rapid and significant reduction of symptoms. The probable mechanism of the therapeutic effect of olanzapine in BMS can include its effect on dopaminergic receptors and probably also on histaminergic, noradrenergic and serotonergic ones.
Psychiatr Pol
PMID:[Burning mouth syndrome: pathogenic and therapeutic concepts]. 2500 31


1 2 Next >>